Compare ARQT & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARQT | AMRX |
|---|---|---|
| Founded | 2016 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.8B |
| IPO Year | 2020 | N/A |
| Metric | ARQT | AMRX |
|---|---|---|
| Price | $28.33 | $12.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $24.83 | $13.25 |
| AVG Volume (30 Days) | ★ 2.0M | 2.0M |
| Earning Date | 10-28-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.02 |
| Revenue | $317,929,000.00 | ★ $2,934,959,000.00 |
| Revenue This Year | $85.51 | $9.99 |
| Revenue Next Year | $30.74 | $6.67 |
| P/E Ratio | ★ N/A | $669.75 |
| Revenue Growth | ★ 129.21 | 9.50 |
| 52 Week Low | $11.13 | $6.69 |
| 52 Week High | $31.77 | $12.82 |
| Indicator | ARQT | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.12 | 62.29 |
| Support Level | $27.55 | $12.14 |
| Resistance Level | $28.90 | $12.53 |
| Average True Range (ATR) | 1.15 | 0.33 |
| MACD | -0.55 | -0.01 |
| Stochastic Oscillator | 18.58 | 80.18 |
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.